Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

William Tillett; Alexander Allen; Laura Tucker; David Chandler; Coziana Ciurtin; Charlotte Davis; Andrew Dick; Amy Foulkes; Nicola Gullick; Philip Helliwell; Deepak Jadon; Gareth Jones; Stuart Kyle; Vishnu Madhok; Neil McHugh; Andrew Parkinson; Tim Raine; Stefan Siebert; Catherine Smith; Laura C Coates

doi:10.1093/rheumatology/keaa526

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

William Tillett, Alexander Allen, Laura Tucker, David Chandler, Coziana Ciurtin, Charlotte Davis, Andrew Dick, Amy Foulkes, Nicola Gullick, Philip Helliwell, Deepak Jadon, Gareth Jones, Stuart Kyle, Vishnu Madhok, Neil McHugh, Andrew Parkinson, Tim Raine, Stefan Siebert, Catherine Smith, Laura C Coates

Research output: Contribution to journal › Article › peer-review

5 Citations (SciVal)

64 Downloads (Pure)

Abstract

The aim of this guideline is to provide an update on evidence-based recommendations for treatment of adult patients with PsA. The previous BSR guidelines for PsA were published in 2012 and since that time, there have been many new advanced therapies licensed for PsA. This update will provide practical guidance for clinicians on the optimal selection of advanced therapies taking into account different domains of PsA (arthritis, enthesitis, dactylitis, axial disease and psoriasis) and key associated comorbidities. It will also update guidance on treatment strategy including the use of a treat-to-target approach. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. (1) This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence (NICE) accreditation.

Original language	English
Article number	keaa526
Pages (from-to)	1588–1592
Journal	Rheumatology (Oxford, England)
Volume	60
Issue number	4
Early online date	23 Oct 2020
DOIs	https://doi.org/10.1093/rheumatology/keaa526
Publication status	Published - 30 Apr 2021

Bibliographical note

Access to Document

10.1093/rheumatology/keaa526

Scope_PsA_biologics_2020_submitted.PDF
This is a pre-copyedited, author-produced version of an article accepted for publication in Rheumatology following peer review. The version of record William Tillett, Alexander Allen, Laura Tucker, David Chandler, Coziana Ciurtin, Charlotte Davis, Andrew Dick, Amy Foulkes, Nicola Gullick, Philip Helliwell, Deepak Jadon, Gareth Jones, Stuart Kyle, Vishnu Madhok, Neil McHugh, Andrew Parkinson, Tim Raine, Stefan Siebert, Catherine Smith, Laura C Coates, Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope, Rheumatology, , keaa526, is available online at: https://doi.org/10.1093/rheumatology/keaa526.
Accepted author manuscript, 246 KB

Cite this

Tillett, W., Allen, A., Tucker, L., Chandler, D., Ciurtin, C., Davis, C., Dick, A., Foulkes, A., Gullick, N., Helliwell, P., Jadon, D., Jones, G., Kyle, S., Madhok, V., McHugh, N., Parkinson, A., Raine, T., Siebert, S., Smith, C., & Coates, L. C. (2021). Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology (Oxford, England), 60(4), 1588–1592. Article keaa526. https://doi.org/10.1093/rheumatology/keaa526

Tillett, W, Allen, A, Tucker, L, Chandler, D, Ciurtin, C, Davis, C, Dick, A, Foulkes, A, Gullick, N, Helliwell, P, Jadon, D, Jones, G, Kyle, S, Madhok, V, McHugh, N, Parkinson, A, Raine, T, Siebert, S, Smith, C & Coates, LC 2021, 'Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope', Rheumatology (Oxford, England), vol. 60, no. 4, keaa526, pp. 1588–1592. https://doi.org/10.1093/rheumatology/keaa526

@article{cc8c2dd214c848bfbc70c60f6f300c9c,

title = "Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope",

abstract = "The aim of this guideline is to provide an update on evidence-based recommendations for treatment of adult patients with PsA. The previous BSR guidelines for PsA were published in 2012 and since that time, there have been many new advanced therapies licensed for PsA. This update will provide practical guidance for clinicians on the optimal selection of advanced therapies taking into account different domains of PsA (arthritis, enthesitis, dactylitis, axial disease and psoriasis) and key associated comorbidities. It will also update guidance on treatment strategy including the use of a treat-to-target approach. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. (1) This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence (NICE) accreditation.",

author = "William Tillett and Alexander Allen and Laura Tucker and David Chandler and Coziana Ciurtin and Charlotte Davis and Andrew Dick and Amy Foulkes and Nicola Gullick and Philip Helliwell and Deepak Jadon and Gareth Jones and Stuart Kyle and Vishnu Madhok and Neil McHugh and Andrew Parkinson and Tim Raine and Stefan Siebert and Catherine Smith and Coates, {Laura C}",

note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: [email protected].",

year = "2021",

month = apr,

day = "30",

doi = "10.1093/rheumatology/keaa526",

language = "English",

volume = "60",

pages = "1588–1592",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

T2 - British Society for Rheumatology guideline scope

AU - Tillett, William

AU - Allen, Alexander

AU - Tucker, Laura

AU - Chandler, David

AU - Ciurtin, Coziana

AU - Davis, Charlotte

AU - Dick, Andrew

AU - Foulkes, Amy

AU - Gullick, Nicola

AU - Helliwell, Philip

AU - Jadon, Deepak

AU - Jones, Gareth

AU - Kyle, Stuart

AU - Madhok, Vishnu

AU - McHugh, Neil

AU - Parkinson, Andrew

AU - Raine, Tim

AU - Siebert, Stefan

AU - Smith, Catherine

AU - Coates, Laura C

PY - 2021/4/30

Y1 - 2021/4/30

N2 - The aim of this guideline is to provide an update on evidence-based recommendations for treatment of adult patients with PsA. The previous BSR guidelines for PsA were published in 2012 and since that time, there have been many new advanced therapies licensed for PsA. This update will provide practical guidance for clinicians on the optimal selection of advanced therapies taking into account different domains of PsA (arthritis, enthesitis, dactylitis, axial disease and psoriasis) and key associated comorbidities. It will also update guidance on treatment strategy including the use of a treat-to-target approach. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. (1) This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence (NICE) accreditation.

AB - The aim of this guideline is to provide an update on evidence-based recommendations for treatment of adult patients with PsA. The previous BSR guidelines for PsA were published in 2012 and since that time, there have been many new advanced therapies licensed for PsA. This update will provide practical guidance for clinicians on the optimal selection of advanced therapies taking into account different domains of PsA (arthritis, enthesitis, dactylitis, axial disease and psoriasis) and key associated comorbidities. It will also update guidance on treatment strategy including the use of a treat-to-target approach. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. (1) This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence (NICE) accreditation.

U2 - 10.1093/rheumatology/keaa526

DO - 10.1093/rheumatology/keaa526

M3 - Article

C2 - 33097948

SN - 1462-0324

VL - 60

SP - 1588

EP - 1592

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - 4

M1 - keaa526

ER -

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this